Leveljump Healthcare Corp (JUMP) Fair Value & Analysis
Healthcare · CA · Market cap C$5.3M
Fair value as of: Jun 26, 2026
From 21 valuation models · updated 4 days ago
Fair value updated Jun 26, 2026 — revised from C$0.2000 to C$0.1348 (−32.6%) since Jun 24, 2026.
Price vs Fair Value (12 months)
12‑month range C$0.0450 – C$0.0800 · fair‑value band C$0.1073 – C$0.1788 · the C$0.0550 price screens below the C$0.1348 fair value. As of Jun 26, 2026.
✦ Find undervalued quality stocks — 35,000+ analysed Find stocks →Analysis
Leveljump Healthcare Corp (JUMP) currently trades at C$0.0550, while our model-based Fair Value estimate is C$0.1348 — implying the stock looks roughly 145.0% undervalued today. We read business quality at 92/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
Over the trailing twelve months, Leveljump Healthcare Corp generated revenue of C$18.9M at a net margin of 10.3%. Revenue grew 8.7% year over year. It earns a return on equity of 36.9%. Net debt stands at C$7.4M. Fundamentals as of Jun 26, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
About the company
Leveljump Healthcare Corp., together with its subsidiaries, provides radiology services. The company offers direct patient images and teleradiology services; in-patient diagnostic imaging facilities, including x-rays, ultrasounds, and mammography; and other medical services. It serves hospitals and clinics. Leveljump Healthcare Corp. is headquartered in Toronto, Canada.
Revenue & earnings trend
FY2020 – FY2024 · reported fiscal years
Leveljump Healthcare Corp reported revenue of C$17.7M in FY2024 versus C$5.5M in FY2020, a compound +34.3%/yr. Reported net income was C$1.2M in FY2024.
Open the full interactive analysis →
Similar stocks
6 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | $464.01 | $326.81 | -30% |
| Danaher Corporation DHR | $183.63 | $87.65 | -52% |
| WuXi AppTec Co WUXAY | $18.59 | $25.09 | +35% |
| IDEXX Laboratories, Inc IDXX | $562.16 | $190.95 | -66% |
| Lonza Group LZAGY | $61.97 | $14.23 | -77% |
| Agilent Technologies, Inc A | $131.62 | $60.93 | -54% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Leveljump Healthcare Corp (JUMP) undervalued?
What is the fair value of JUMP?
What is the quality score of JUMP?
What is the revenue of Leveljump Healthcare Corp (JUMP)?
What is the net profit margin of JUMP?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.